During the 15th Annual Healthcare Industry Leadership Virtual Conference, A&M experts discussed how COVID-19 has propelled the biotech and pharmaceutical industry – vaccine production, research and innovation and opportunities for investment – tenfold in just a few short months.
In this session, the panelists also discussed:
- Near- and long-term industry outlook
- Expanded patient access for clinical trials
- Developing regulatory challenges
- Emerging players and platforms
- Expanding role for telehealth
Panel Moderator:
Dr. Keith Ghezzi, Managing Director, A&M Healthcare Industry Group
Speakers:
Jacques Mulder, former Managing Director, A&M Healthcare Industry Group
Peter Urbanowicz, Managing Director and Co-Head of A&M's Healthcare Industry Group
Watch the other panel sessions here:
Healthcare Systems in the COVID-19 Era
Diversity & Inclusion in Healthcare Organizations
Disruption in the ACA Market – Implications and Strategic Responses
June 11, 2025
In a recent article, A&M Healthcare Industry Group experts explore key policy changes, market dynamics, stakeholder implications and strategic actions for navigating the evolving landscape surrounding the Affordable Care Act marketplace.
The Effect of Trump’s Tariffs on the European Pharmaceutical and Biopharmaceutical Industry
June 9, 2025
As the U.S. considers imposing tariffs on European pharmaceutical imports, the ripple effects could
be felt across the global healthcare landscape.
FORMER FEDERAL HEALTH MINISTER PROFESSOR GREG HUNT JOINS ALVAREZ & MARSAL AUSTRALIA
May 27, 2025
Alvarez & Marsal appoints The Honourable Greg Hunt as a Senior Advisor bolstering its Healthcare and Public Sector advisories in support of maximizing sustainable value for clients.
Contract Research Organisations M&A Market
March 28, 2025
Rising cost pressures, stricter regulatory demands and advancements in emerging therapeutics are intensifying competition within the industry. These dynamics are fuelling the demand for greater efficiency in development lifecycles, creating significant opportunities for outsourced providers like Contract Research Organisations (CROs).
